XNASVKTX
Market cap4.52bUSD
Jan 08, Last price
40.60USD
1D
-2.54%
1Q
-34.99%
Jan 2017
3,311.76%
IPO
361.36%
Name
Viking Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.38%
Rev. gr., 5y
%
Revenues
0k
Net income
-86m
L+27.48%
CFO
-73m
L+51.61%
Earnings
Feb 05, 2025
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 101,119 | 70,646 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (101,119) | (70,646) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,488) | ||||||||
Tax Rate | |||||||||
NOPAT | (101,119) | (69,158) | |||||||
Net income | (85,895) 27.48% | (67,379) 24.77% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (7,121) | (5,969) | |||||||
BB yield | 0.41% | 0.83% | |||||||
| Debt | |||||||||
Debt current | 648 | 304 | |||||||
Long-term debt | 2,196 | 2,824 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (359,235) | (152,357) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (73,376) | (48,397) | |||||||
CAPEX | |||||||||
Cash from investing activities | (179,086) | 54,753 | |||||||
Cash from financing activities | 271,376 | 4,163 | |||||||
FCF | (100,827) | (70,551) | |||||||
| Balance | |||||||||
Cash | 362,079 | 155,485 | |||||||
Long term investments | |||||||||
Excess cash | 362,079 | 155,485 | |||||||
Stockholders' equity | (378,332) | (293,150) | |||||||
Invested Capital | 728,335 | 440,036 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 94,347 | 76,834 | |||||||
Price | 18.61 97.98% | 9.40 104.35% | |||||||
Market cap | 1,755,798 143.10% | 722,240 103.39% | |||||||
EV | 1,396,563 | 569,883 | |||||||
EBITDA | (100,827) | (70,355) | |||||||
EV/EBITDA | |||||||||
Interest | 88 | 1,488 | |||||||
Interest/NOPBT | |||||||||